Golden Biotechnology Corporation acquires patent in the U.S. for the treatment of neurodegenerative diseases and patent in Japan for the treatment of arteriosclerosis diseases

Golden Biotechnology Corporation (GBC) is an international company based in Taiwan that has been dedicated to manufacturing natural products that improve human health by preventing and curing pathologies since 2002. It recently acquired a patent in the United States to treat neurodegenerative diseases and another patent in Japan to treat arteriosclerosis.

Patent in the United States
The Patent and Trademark Office in the United States approved a patent for the drug Antroquinonol, which is included in the “Methods and Compositions for the Treatment of Neurodegenerative Diseases.” This compound seeks to reduce the risk of diseases caused by neural damage, in addition to alleviating, improving, and minimizing symptoms.

GBC hopes to find success against various pathological disorders like Alzheimer’s, Parkinson’s, multiple sclerosis, cerebrovascular syndromes from accidents, Down syndrome and lateral amyotrophic sclerosis.

This is not the first time the company has acquired a patent of this type; in 2016 it acquired such a patent in Taiwan. At the same time it applied for patents in about 50 countries from around the world with the goal of finding an effective remedy against neurodegenerative diseases.

Among the approved studies one that stands out is the possibility of inhibiting neural damage caused by the accumulation of excessive beta-amyloid in the body. This substance negatively affects the brain and contributes to the development of Alzheimer’s, a significant public health issue.

GBC has been working with the Institute of Health and Biomedical Innovation from the Queensland University of Technology (Australia) on realizing preclinical experiments with Antroquinonol. This compound promotes innovative and potent effects on the prevention of Alzheimer’s disease.

This investigation that focused on developing a potential treatment against Alzheimer’s is the reason GBC was the recipient of an award in the 2016 Advance Queensland –Johnson & Johnson Innovation QuickFire Challenge in Australia. They were recognized in the pharmaceutical category.

Ever since the successful preclinical trials on the effectiveness of Antroquinonol, many institutional cooperative agreements have been arranged to plan and execute clinical trials to help test the benefits of this drug.

Patent in Japan
Another of the patents obtained by Golden Biotechnology Corporation is one that was approved by the Japan Patent Office (JPO), which focuses on “Methods and Compositions for the Treatment of Arteriosclerosis –related Vascular Diseases.”

The vascular disease arteriosclerosis manifests itself when the arterial wall accumulates adipose substances, causing the wall to get thicker than normal, producing hardening and obstruction in the flow of arteries.

Based on this new patent, GBC will apply compounds therapeutically to effectively inhibit the effects of arteriosclerosis.

This will be done in the hopes that said substances will minimize the propagation of adipose cells with the goal of reducing the formation of neointima and maintain a normal level of lipoprotein cholesterol of low density in the blood.

The patent obtained in Japan also includes the possibility of investigating the effects of natural products on other pathologies, such as arterial coronary disease, aneurisms, myocardic infarction, embolisms, apoplexy, thrombosis and related afflictions.

Golden Biotechnology Corporation continues to focus on discovering new drugs that can improve people’s quality of life. It current has over 100 patents related to Antroquinonol.

This innovative dietary product is being tested in various distinct clinical trials with the objective of measuring its efficacy against non-small cell lung cancer and other diseases.